2015
DOI: 10.1093/ejcts/ezu539
|View full text |Cite
|
Sign up to set email alerts
|

Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support

Abstract: cf-LVAD support is associated with lengthening of cardiomyocytes, without alterations in diameter size. Remarkably, myocardial fibrosis increased as well as circulating pro-fibrotic markers. Whether the morphological changes are a direct effect of reduced pulsatility during cf-LVAD support or due to HF progression requires further investigation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
16
2
2

Year Published

2015
2015
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 41 publications
(23 citation statements)
references
References 24 publications
3
16
2
2
Order By: Relevance
“…14 Similarly, high Gal-3 levels were found in LV from patients at BIBLIOTHEQUE DE L'UNIV LAVAL on October 11, 2015 http://hyper.ahajournals.org/ Downloaded from with advanced HF, which were accompanied by fibrosis. 19,33 In addition, the inhibition of Gal-3 activity normalized CCL2, osteopontin, and superoxide anion levels at both cardiac and vascular levels in obese animals supporting that Gal-3 could also participate in cardiovascular remodeling associated with obesity through its proinflammatory and prooxidants actions. Therefore, our results build and extend on the context of obesity, an initial stage of HF, previous observations in which Gal-3 is associated with cardiac fibrosis in different settings, including nonischemic dilated cardiomyopathy, hyperaldosteronism, HF, or acute myocardial infarction.…”
Section: Discussionmentioning
confidence: 92%
“…14 Similarly, high Gal-3 levels were found in LV from patients at BIBLIOTHEQUE DE L'UNIV LAVAL on October 11, 2015 http://hyper.ahajournals.org/ Downloaded from with advanced HF, which were accompanied by fibrosis. 19,33 In addition, the inhibition of Gal-3 activity normalized CCL2, osteopontin, and superoxide anion levels at both cardiac and vascular levels in obese animals supporting that Gal-3 could also participate in cardiovascular remodeling associated with obesity through its proinflammatory and prooxidants actions. Therefore, our results build and extend on the context of obesity, an initial stage of HF, previous observations in which Gal-3 is associated with cardiac fibrosis in different settings, including nonischemic dilated cardiomyopathy, hyperaldosteronism, HF, or acute myocardial infarction.…”
Section: Discussionmentioning
confidence: 92%
“…Vasilieva 3 , A.O. Shevchenko 1,2,3 Objective: to determine the diagnostic value of galectin-3 in transplant recipients with myocardial fibrosis and acute heart transplant rejection, verified by endomyocardial biopsy. Materials and methods.…”
Section: Diagnostic Value Of Galectin-3 In Heart Transplant Recipientmentioning
confidence: 99%
“…Особое внимание уделяется выявлению профиброгенных биологических агентов, способных быть индикаторами риска негативных сердечно-сосудистых событий, связанных с развитием фиброза [2,3]. К числу относительно недавно описанных биомаркеров развития сердечной недостаточности и фиброза миокарда относится галектин-3, принадлежащий к семейству лектинов и играющий важную роль в регуляции процессов пролиферации миофибробластов, иммунного ответа, воспаления и ремоделирования сосудов сердца [4,5].…”
unclassified
“…Это способствует снижению притока кислорода и питательных веществ к кардиомиоцитам, замедляет прохождение по ним нервных импульсов [25]. Галектин-3 был идентифицирован как фактор, влияющий на развитие фиброза в миокарде [26]. В эксперименте на лабораторных животных установлено, что в ответ на стимуляцию альдостероном макрофаги начинают экспрессию галектина-3, который является стимулом пролиферации фибробластов и выработки коллагена в миокарде [27,28].…”
Section: галектин-3 при фиброзе миокардаunclassified